Son güncelleme :
08/05/2024
Antibiyotik   Aztreonam  
Enjeksiyon
Çözeltilerin stabilitesi Karışımlardaki stabilitesi Stabiliteyi etkileyen faktörler Uyumluluk Uygulama yöntemi Kaynaklar Pdf
   Kimyasal yapı   

Ticari isim   Ticari isim     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Azactam Almanya, Amerika Birleşik Devletleri, Avustralya, Avusturya, Belçika, Birleşik Arap Emirlikleri, Brezilya, Büyük Britanya, Danimarka, Ekvador, Finlandiya, Fransa, Hollanda, İrlanda, İspanya, İsveç, İsviçre, İtalya, Japonya, Kolombiya, Lüksemburg, Norveç, Polonya, Portekiz, Şili, Yeni Zelanda, Yunanistan
Azaxil Brezilya
Azthreonam Amerika Birleşik Devletleri, Arjantin, Brezilya, Kolombiya, Peru, Şili, Venezuela
Barex İspanya
Cayston Almanya, Amerika Birleşik Devletleri, Belçika, İspanya, İsviçre, Kanada
Monobac Meksika
Namy Hindistan
Primbactam İtalya
Treonam Peru
Urobactam İspanya
Vibactam Peru
Kaynaklar   Enjeksiyon    Kaynaklar : Aztreonam  
Tip Yayın
3 Dergi Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
19 Dergi Bell RG, Lipford LC, Massanari MJ, Riley CM.
Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin.
Am J Hosp Pharm 1986 ; 43: 1444-1453.
59 Dergi Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62 Dergi Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125.
73 Dergi Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
81 Dergi Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Dergi Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
94 Dergi Chandler SW, Folstad J, Trissel LA.
Aztreonam-vancomycin incompatibility.
Am J Hosp Pharm 1990 ; 47: 1970.
99 Dergi Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
129 Dergi Smythe M, Malouf E.
Visual compatibility of insulin with secondary intravenous drugs in admixtures.
Am J Hosp Pharm 1991 ; 48: 125-126.
169 Dergi Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Dergi Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
198 Dergi Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
244 Dergi Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Dergi Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Dergi Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253 Dergi Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528.
258 Dergi Belliveau PP, Nightingale CH, Quintiliani R.
Stability of aztreonam and ampicillin sodium-sulbactam sodium in 0.9% sodium chloride injection.
Am J Hosp Pharm 1994 ; 51: 901-904.
284 Dergi Trissel LA, Xu QA, Martinez JF.
Compatibility and stability of aztreonam and vancomycin hydrochloride.
Am J Health-Syst Pharm 1995 ; 52: 2560-2564.
285 Dergi Elmore RL, Contois ME, Kelly J, Noe A, Poirier A.
Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs.
Clin Ther 1996 ; 18: 246-255.
299 Dergi Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Dergi Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Dergi Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Dergi Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
317 Dergi Kershaw BP, Monnier HL, Mason JH.
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Am J Hosp Pharm 1993 ; 50: 1360-1362.
334 Dergi Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Dergi Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
337 Dergi Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
360 Dergi Inagaki K, Gill MA, Okamoto MP, Takagi J.
Stability of ranitidine hydrochloride with aztreonam, ceftazidime, or piperacillin sodium during simulated Y-site administration.
Am J Hosp Pharm 1992 ; 49: 2769-2772.
419 Dergi James MJ, Riley CM.
Stability of intravenous admixtures of aztreonam and clindamycin phosphate.
Am J Hosp Pharm 1985 ; 42: 1984-1986.
422 Dergi James MJ, Riley CM.
Stability of intravenous admixtures of aztreonam and ampicillin.
Am J Hosp Pharm 1985 ; 42: 1095-1100.
426 Dergi Riley CM, James MJ.
Stability of intravenous admixtures containing aztreonam and cefazolin.
Am J Hosp Pharm 1986 ; 43: 925-927.
432 Dergi Marble DA, Bosso JA, Townsend RJ.
Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions.
Am J Hosp Pharm 1986 ; 43: 1732-1736.
433 Dergi Riley CM, Lipford LC.
Interaction of aztreonam with nafcillin in intravenous admixtures.
Am J Hosp Pharm 1986 ; 43: 2221-2224.
492 Dergi Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
496 Dergi Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
500 Dergi Tucker DR, Sieradzan R.
Visual compatibility of ciprofloxacin lactate with five broad-spectrum antimicrobial agents during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1910-1911.
604 Laboratuar Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998
644 Dergi Marble DA, Bosso JA, Townsend RJ.
Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles.
Drug Intell Clin Pharm 1988 ; 22: 54-57.
905 Dergi Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Dergi Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1064 Dergi Vinks AATMM, Touw DJ, van Rossen RCJM, Heijeiman HGM, Bakker W.
Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatement (HIVAT).
Pharm World Sci 1996 ; 18: 74-77.
1135 Dergi Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077.
1233 Dergi McLaughlin JP, Simpson C.
The stability of reconstituted aztreonam.
Br J Pharm Pract 1990 ; 12: 328, 330, 334.
1315 Dergi Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410 Dergi Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Dergi Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Dergi Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1490 Dergi Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1513 Laboratuar Quinupristine / dalfopristine (Synercid®) - Résumé des caractéristiques du produit
Monarch Pharmaceuticals Ireland 2006
1625 Dergi Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1658 Dergi Zhang Y, Xu QA, Trissel LA, Willimas KY.
Compatibility and stability of linezolid injection admixed with aztreonam or piperacillin sodium.
J Am Pharm Assoc 2000 ; 40: 520-524.
1712 Dergi Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Dergi Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Dergi Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 Dergi Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1800 Dergi Voytilla KL, Tyler LS, Rusho WJ.
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.
Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803 Dergi Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925 Dergi Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1937 Dergi Lai JJ, Brodeur SK.
Physical and chemical stability of daptomycin with nine medications.
Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1953 Dergi Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2042 Dergi Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM.
Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).
Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2233 Dergi Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247 Dergi Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2263 Dergi Zajac M, Jelinska A, Cielecka-Piontek J, Osqczapowicz I.
Stability of aztreonam in AZACTAM.
Il Farmaco 2005 ; 60: 599-603.
2271 Laboratuar Daptomycine (Cubicin®) Résumé des caractéristiques du produits
Novartis 2006
3152 Dergi Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3526 Laboratuar Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010
3547 Laboratuar Aztréonam (Azactam®) - Résumé des caractéristiques du produit
Sanofi-Aventis France 2011
3549 Laboratuar Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3595 Laboratuar Aciclovir - Summary of Product Characteristics
Hospira 2009
3674 Laboratuar Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3791 Afiş Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014
3827 Afiş Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Afiş Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Afiş So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
4055 Dergi Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Dergi Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319 Dergi Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4326 Dergi Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P.
Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion.
Pharmazie 2019 ; 74: 357-362.
4389 Dergi Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4434 Dergi Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4456 Dergi Tobudic S, Prager I, Kussmann M, Obermüller M, Ursli M, Zeitlinger M, Wiesholzer M, Burgmann H, Poeppl W, Reznicek G.
Compatibility of aztreonam in four commercial peritoneal dialysis fluids.
Scientific reports 2020 10:1788
4528 Dergi Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4548 Dergi O'Donnell J.N, Xu A, Lodise T.P.
Intravenous Compatibility of Ceftazidime/Avibactam and Aztreonam Using Simulated and Actual Y-site Administration.
Clin Ther 2020 ; 42, 8: 1580-1586.
4634 Dergi Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A.
Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.
Antibiotics 2022 ;11,4: 458
4801 Dergi Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:

  Mentions Légales